Addressing HPV vaccination concerns

March 11, 2020

(Boston, MA) -Research from the Harvard Pilgrim Health Care Institute finds a promising avenue for addressing vaccine hesitancy around HPV vaccine. The study, "Tailored Messages Addressing HPV Vaccination Concerns Improves Behavioral Intent Among Mothers: A Randomized Controlled Trial," appears in the xx issue of the Journal of Adolescent Health.

The HPV vaccine is highly effective in preventing infection against certain types of HPV that can lead to cervical, oropharyngeal, and anal cancers. However, HPV vaccine coverage in pre-teens and young teens remains sub-optimal, with only 61% of 13-year-old girls and 64% of 13-year-old boys in the U.S. initiating the vaccine series, with wide variation across states. Parental hesitancy is one reason for low vaccination coverage. In fact, vaccine hesitancy in general has been identified as one of the top ten global health threats by the WHO, which suggests the strong need for work addressing this issue. When recommending HPV vaccine, the current guidelines suggest clinicians use a presumptive, bundled messaging approach, in which a provider presumes that the parent is ready to vaccinate and states that the child is "due" for all age-appropriate vaccines at the 11-12 year old well-visit appointment, including HPV vaccine. However, this approach, by itself, may not be the most effective strategy for parents with specific concerns about the HPV vaccine.

In a large web-based randomized controlled trial of mothers with concerns about the HPV vaccine, investigators compared the impact of implementing the current guideline alone and in combination with tailored messages on HPV vaccination intent. These mothers, all of whom did not intent to vaccinate their 11-14 year-old child within the next 12 months, were randomized to one of three groups: a) "control" which watched a bundled recommendation video; b) "top concern" which watched the control video plus a video tailored to their top HPV vaccine concern; or c) "all concerns" which watched the control video plus videos on the top 5 most common HPV vaccine concerns.

Study results found that tailored messages addressing all of the specific concerns of vaccine hesitant mothers improved HPV vaccination intent, and tailored messages addressing the top concern marginally improved intent; these improvements were not observed in the control group.

"We found that a presumptive, bundled messaging approach, by itself, may not be the most effective strategy for increasing HPV vaccine uptake in pre-teens and young teens who have parents with specific concerns about the vaccine," said co-lead author Catherine Panozzo, PhD, Assistant Professor of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School. Adds Dr. Panozzo,, "our findings contribute to the growing body of literature suggesting that tailored recommendations may be essential for improving HPV vaccination acceptance among hesitant parents".

Regarding future directions, co-lead author, Dr. Katharine Head, Assistant Professor of Communication Studies at Indiana University School of Liberal Arts, commented, "We suggest that future studies determine whether these improvements in HPV vaccination intent can translate to actual improvements in HPV vaccination in clinic settings. In fact, our team is working to integrate these messaging strategies into a clinical intervention to test this very hypothesis."
-end-
About Harvard Pilgrim Health Care Institute's Department of Population Medicine

The Harvard Pilgrim Health Care Institute's Department of Population Medicine is a unique collaboration between Harvard Pilgrim Health Care and Harvard Medical School. Created in 1992, it was the first medical school department in the United States based in a health plan. The Institute focuses on improving health care delivery and population health through innovative research and teaching.

More Information

Tailored Messages Addressing HPV Vaccination Concerns Improves Behavioral Intent Among Mothers: A Randomized Controlled Trial is co-authored by investigators from: Indiana University School of Liberal Arts, Department of Communication Studies; Department of Family & Community Health, University of Pennsylvania School of Nursing; Vaccine Education Center, Children's Hospital of Philadelphia/ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania/ Philadelphia Department of Public Health, Division of Disease Control; Department of Pediatrics, Indiana University School of Medicine.

Harvard Pilgrim Health Care Institute

Related Hpv Vaccine Articles from Brightsurf:

Study shows social media policies can curb HPV vaccine misinformation
A new study led by VCU Massey Cancer Center researcher Jeanine Guidry, Ph.D., compared how HPV vaccination was portrayed on Pinterest before and after the social media platform began moderating vaccine-related content.

Parents of 1 in 2 unvaccinated US adolescents have no intention to initiate HPV vaccine
Study results documenting parental hesitancy to begin and complete their child's HPV vaccine series were published in The Lancet Public Health by researchers at The University of Texas Health Science Center at Houston (UTHealth).

Study: 'Anti-vaxxers' gain traction against HPV vaccine on Facebook
One of the biggest social media sites -- Facebook -- has allowed ''anti-vaxxers'' to gain a stronger voice against the use of the human papillomavirus, or HPV, vaccine, according to a new study from a media expert at the University of Missouri.

Therapeutic HPV vaccine may improve outcomes in advanced cervical cancer
Combining a therapeutic vaccine for human papilloma virus (HPV) with two standard chemotherapy drugs may extend survival in patients with advanced, recurrent cervical cancer, according to a phase 1/2 trial involving 77 patients.

HPV vaccine hesitancy in Japan could result in 5,000 additional death
The precipitous drop in HPV vaccination rates after suspension of proactive recommendations by the government in 2013 could result in an additional 25,000 cervical cancer cases and more than 5,000 additional deaths among females born between 1994 to 2007 in Japan.

Single HPV vaccine dose may be effective against cervical cancer
New research published in CANCER indicates that a single dose of the human papillomavirus (HPV) vaccine is as effective as multiple doses for preventing preinvasive cervical disease, which can later develop into cervical cancer.

Physicians report high refusal rates for the HPV vaccine and need for improvement
Despite its proven success at preventing cancer, many adolescents are still not getting the HPV vaccine.

One dose of HPV vaccine may be enough, Australian research finds
One dose of human papillomavirus (HPV) vaccine has comparable effectiveness to 2 or 3 doses for preventing cervical pre-cancer, according to a new study.

HPV vaccine coverage is far behind other infant vaccines in many US states
Trends in HPV vaccine uptake in children in the US.

Two types of HPV linked to cervical cancer have declined since the advent of the HPV vaccine
An analysis of cervical precancers over a period of seven years showed that two strains of human papillomavirus (HPV) that have been targeted by vaccination since 2006 have declined, accounting for a smaller proportion of cervical disease.

Read More: Hpv Vaccine News and Hpv Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.